CaseVu
Precipio Enters India Liquid Biopsy Market With Adoption By Leading Laboratory
CORE Diagnostics to transition to Precipio’s price competitive ICE COLD-PCR™ platform NEW HAVEN, CT, (March [...]
Mar
Precipio Restructures Capitalization Table
Investors to convert preferred shares and exercise warrants NEW HAVEN, CT, (March 22nd, 2018) – Specialty [...]
Mar
Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform
Enhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – [...]
Mar
Precipio Settles Lawsuit With Crede Capital
Completes Restructuring of close to 95% Transgenomic Liabilities NEW HAVEN, CT, (March 13th, 2018) – Specialty [...]
Mar
Key Measure Of Precipio’s Pathology Sales Growth 4X Prior Quarter
Strong indications of academic-level pathology market adoption and sales uptake NEW HAVEN, CT, (February 22nd, [...]
Feb
Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance
New test fulfills promise of liquid biopsies to cost effectively monitor patients NEW HAVEN, CT, [...]
Feb
Precipio Announces Q4 2017 Revenue At 350% Of Previous Quarter
First post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 09th, [...]
Feb
Precipio Enters Japanese Liquid Biopsy Market With First Hospital Sale
First ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company NEW HAVEN, CT, [...]
Feb
Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania
NEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it [...]
Jan
Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion
Sales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, [...]
Jan